This content is from: Premium
Perceptive Advisors Poised to Benefit from Biopharma IPO
The health care-focused hedge fund firm plans to add to its stake when Kodiak Sciences goes public next week.
It may not be one of those hot-shot internet unicorns, but when Kodiak Sciences goes public — possibly next Wednesday — at least one hedge fund firm stands to benefit in a big way. Joseph Edelman’s Perceptive Advisors is an investor in the development-stage biopharmaceutical company, which on Monday set in
To continue reading, subscribe now to Premium Journalism. Already a subscriber? Login.